Does Orlistat Affect Levothyroxine Bioavailability?
Yıl: 2022 Cilt: 6 Sayı: 1 Sayfa Aralığı: 22 - 27 Metin Dili: İngilizce DOI: 10.14744/ejmi.2022.40513 İndeks Tarihi: 11-07-2022
Does Orlistat Affect Levothyroxine Bioavailability?
Öz: Objectives: Orlistat is used in the treatment of obesity while hypothyroidism is treated with levothyroxine. In this study, the effect of orlistat treatment on thyroid stimulating hormone (TSH) was investigated.
Methods: The files of the patients who were followed up with the diagnosis of obesity and hypothyroidism were evaluated retrospectively. Patients with a body mass index (BMI) > 40 and receiving levothyroxine replacement therapy were included in the study. Group 1 consisted of 37 patients who received orlistat and levothyroxine while group 2 consisted of patients who received levothyroxine without orlistat. BMI and TSH values of patients were compared at baseline and at third month.
Results: Despite group 1 having mild increase in TSH at third month compared to baseline, no statistically significant difference was observed (p:0.328). No differences were observed between TSH values of group 2 at baseline and third month (p: 0.380). When BMI of group 1 were compared at baseline and third month, it was found to be statistically lower (p<0.01). In group 2, BMI were significantly lower when baseline values were compared with third month (p<0.01).
Conclusion: It would be appropriate to closely monitor thyroid function tests in patients on levothyroxine following initiation of orlistat treatment.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Bibliyografik
- 1. WHO. Obesity: preventing and managing the global epidemic. Technical report series No. 894, Geneva: WHO; 2000.
- 2. Hollander PA. Orlistat. Drugs 2001;61:2120–21.
- 3. Lee M, Lauren BN, Zhan T, Choi J, Klebanoff M, Abu Dayyeh B, et al. The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. Obes Sci Pract 2019;6:162–70.
- 4. Cahill A, Lean MEJ: Review article: malnutrition and maltreatment: a comment on orlistat for the treatment of obesity. Aliment Pharmacol Ther 1999;13:997–1002.
- 5. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet 2017;390:1550–62.
- 6. Akagunduz B, Akcakaya M. Evaluation of the correlation of urea, creatine, and uric acid levels with TSH in patients with newly diagnosed overt and subclinic hypothyroidism. EJMI 2021;5:317–21.
- 7. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008;31:53–65.
- 8. Sweetman S. Martindale: the complete drug reference. London: Pharmaceutical Press. Available at:http://www.medicinescomplete.com/mc/martindale/current/9000-a5-z.html. Accessed Jan 2, 2014.
- 9. Madhava K, Hartley A. Hypothyroidism in thyroid carcinoma follow-up: orlistat may inhibit the absorption of thyroxine. Clin Oncol (R Coll Radiol) 2005;17:492.
- 10. Chiffoleau A, De Mallmann V, Lambert J, Bodin X. Interaction between orlistat and levothyroxine: a first French case report. Fundam Clin Pharmacol 2010;24:1–1.
- 11. Pai MP, Paloucek FP. The origin of the “ideal” body weight equations. Ann Pharmacother 2000;34:1066–9.
- 12. McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002;10:642–50.
- 13. Benvenga S. L-T4 Therapy in the Presence of Pharmacological Interferents. Front Endocrinol (Lausanne) 2020;11:607446.
- 14. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167–72.
- 15. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000;160:1321–6
| APA | Aydın B (2022). Does Orlistat Affect Levothyroxine Bioavailability?. , 22 - 27. 10.14744/ejmi.2022.40513 |
| Chicago | Aydın Bünyamin Does Orlistat Affect Levothyroxine Bioavailability?. (2022): 22 - 27. 10.14744/ejmi.2022.40513 |
| MLA | Aydın Bünyamin Does Orlistat Affect Levothyroxine Bioavailability?. , 2022, ss.22 - 27. 10.14744/ejmi.2022.40513 |
| AMA | Aydın B Does Orlistat Affect Levothyroxine Bioavailability?. . 2022; 22 - 27. 10.14744/ejmi.2022.40513 |
| Vancouver | Aydın B Does Orlistat Affect Levothyroxine Bioavailability?. . 2022; 22 - 27. 10.14744/ejmi.2022.40513 |
| IEEE | Aydın B "Does Orlistat Affect Levothyroxine Bioavailability?." , ss.22 - 27, 2022. 10.14744/ejmi.2022.40513 |
| ISNAD | Aydın, Bünyamin. "Does Orlistat Affect Levothyroxine Bioavailability?". (2022), 22-27. https://doi.org/10.14744/ejmi.2022.40513 |
| APA | Aydın B (2022). Does Orlistat Affect Levothyroxine Bioavailability?. Eurasian Journal of Medical Investigation, 6(1), 22 - 27. 10.14744/ejmi.2022.40513 |
| Chicago | Aydın Bünyamin Does Orlistat Affect Levothyroxine Bioavailability?. Eurasian Journal of Medical Investigation 6, no.1 (2022): 22 - 27. 10.14744/ejmi.2022.40513 |
| MLA | Aydın Bünyamin Does Orlistat Affect Levothyroxine Bioavailability?. Eurasian Journal of Medical Investigation, vol.6, no.1, 2022, ss.22 - 27. 10.14744/ejmi.2022.40513 |
| AMA | Aydın B Does Orlistat Affect Levothyroxine Bioavailability?. Eurasian Journal of Medical Investigation. 2022; 6(1): 22 - 27. 10.14744/ejmi.2022.40513 |
| Vancouver | Aydın B Does Orlistat Affect Levothyroxine Bioavailability?. Eurasian Journal of Medical Investigation. 2022; 6(1): 22 - 27. 10.14744/ejmi.2022.40513 |
| IEEE | Aydın B "Does Orlistat Affect Levothyroxine Bioavailability?." Eurasian Journal of Medical Investigation, 6, ss.22 - 27, 2022. 10.14744/ejmi.2022.40513 |
| ISNAD | Aydın, Bünyamin. "Does Orlistat Affect Levothyroxine Bioavailability?". Eurasian Journal of Medical Investigation 6/1 (2022), 22-27. https://doi.org/10.14744/ejmi.2022.40513 |
